Esperion (ESPR) AI Stock Analysis

• Market Cap: $237.42M
• Dividend Yield: N/A
• Average Volume (3M): 4.49M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.00
• Revenue Growth: 185.66%
• EPS Growth: 89.22%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 78
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.27
• Shares Outstanding: 197,848,890
• 10 Day Avg. Volume: 4,299,510
• 30 Day Avg. Volume: 4,489,475
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.01
• Price to Cash Flow (P/CF): -2.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.20
• Price Target Upside: 579.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

Esperion's stock score is primarily influenced by financial instability and technical weakness. Despite strong revenue growth and strategic partnerships noted in the earnings call, the company's negative profitability, high debt levels, and bearish market indicators weigh heavily on its overall performance.

Positive Factors

Drug Development

Esperion Therapeutics has shown significant potential in its drug development pipeline.

Revenue Growth

Esperion's financials show a significant U.S. net product revenue growth of 52% year-over-year in 4Q24.

Strategic Partnerships

Esperion Therapeutics has made strategic partnerships that could enhance its growth opportunities.

Negative Factors

Competitive Landscape

There are concerns about the competitive landscape which may impact Esperion Therapeutics' market position.

Regulatory Challenges

Challenges in regulatory approvals could pose risks to Esperion Therapeutics' future prospects.

Sales Performance

US sales of bempedoic acid (BA) missed by -$3M (-8%), marking the 3rd consecutive quarter the franchise has come in below.

Esperion Business Overview & Revenue Model

Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

How the Company Makes Money

Esperion makes money primarily through the sales of its FDA-approved oral therapies, including bempedoic acid and the bempedoic acid/ezetimibe combination tablet, marketed under the brand names NEXLETOL and NEXLIZET. The company's revenue model is centered around the commercial distribution of these cholesterol-lowering medications to healthcare providers, pharmacies, and directly to patients. Esperion's earnings are also bolstered by strategic partnerships and licensing agreements that expand the reach and distribution of its products in international markets. Additionally, the company may earn milestone and royalty payments through collaborations with other pharmaceutical companies.

Esperion Financial Statement Overview

Summary

Esperion demonstrates strong revenue growth but faces challenges with profitability and financial stability. The company has negative net income and high debt levels, with a reliance on debt financing. Cash flows are improving but remain negative, indicating ongoing financial risks.

Income Statement

Esperion's revenue increased significantly from 2023 to 2024, demonstrating a strong growth trajectory in the income statement. However, the company continues to face challenges with profitability, as evidenced by negative net income, resulting in a negative net profit margin. The gross profit margin remains high, indicating efficient cost management relative to revenue, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows significant financial leverage with a negative stockholders' equity, indicating potential financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which is a red flag. Total debt is substantial, and the equity ratio is negative, suggesting the company is heavily reliant on debt financing. The negative return on equity further highlights profitability challenges.

Cash Flow

Esperion's cash flow statement reveals improving free cash flow, although it remains negative. Operating cash flow is also negative, which raises concerns about the sustainability of operations without external financing. The free cash flow to net income ratio is not favorable due to persistent losses, though the operating cash flow to net income ratio suggests some efficiency in cash management relative to net losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
332.31M	116.33M	75.47M	78.45M	227.55M
	Gross Profit
332.31M	73.07M	48.51M	64.23M	225.16M
	EBIT
54.40M	-155.56M	-179.50M	-226.73M	-121.40M
	EBITDA
7.57M	-150.11M	-176.35M	-222.14M	-120.33M
	Net Income Common Stockholders
-51.74M	-209.25M	-287.82M	-318.82M	-166.19M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
144.76M	82.25M	124.78M	208.89M	304.96M
	Total Assets
343.82M	205.80M	247.94M	381.59M	353.26M
	Total Debt
297.60M	540.95M	260.95M	260.20M	185.41M
	Net Debt
152.84M	458.70M	136.17M	51.30M	-119.55M
	Total Liabilities
732.54M	660.79M	571.72M	578.53M	449.39M
	Stockholders Equity
-388.72M	-454.99M	-1.34B	-1.11B	-838.82M
Cash Flow		Free Cash Flow
-23.97M	-135.49M	-174.83M	-263.81M	-98.55M
	Operating Cash Flow
-23.65M	-135.49M	-174.83M	-263.81M	-85.18M
	Investing Cash Flow
-317.00K	42.50M	8.10M	-50.48M	21.36M
	Financing Cash Flow
86.48M	50.46M	32.61M	268.22M	201.72M

Esperion Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ESPR, the sentiment is Negative. The current price of 1.06 is below the 20-day moving average (MA) of 1.49, below the 50-day MA of 1.66, and below the 200-day MA of 2.05, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 34.45 is Neutral, neither overbought nor oversold. The STOCH value of 10.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ESPR.

Esperion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	78 Outperform	$62.69B	14.96	15.95%	0.15%	8.27%	10.35%
VRTX	64 Neutral	$122.00B	―	-3.15%	―	11.64%	-114.72%
MDGL	54 Neutral	$6.94B	―	-80.35%	―	―	-10.89%
Sector *	48 Neutral	$6.27B	1.17	-48.19%	2.68%	17.28%	1.24%
AMRN	44 Neutral	$165.70M	―	-15.79%	―	-25.86%	-37.14%
ESPR	40 Underperform	$237.42M	―	23.44%	―	185.66%	89.22%
NVAX	39 Underperform	$1.00B	―	30.06%	―	-30.65%	77.62%

Esperion Corporate Events

Esperion Appoints Robert E. Hoffman as New Director

On April 1, 2025, Esperion Therapeutics announced the appointment of Robert E. Hoffman as an independent director and Chairperson of the Audit Committee, effective May 29, 2025. This follows the resignation of board members Nicole Vitullo and Antonio M. Gotto, Jr., effective June 1, 2025. Hoffman’s extensive experience in the biopharmaceutical sector is expected to support Esperion’s growth and commercialization efforts, particularly in expanding its pipeline of ACLY inhibitors.